CD96
Alpha Lifetech can provide CD96 corresponding products, help each customer's research and development.
01
Introduction To CD96
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to CD96 protein is a common target in medicine.
CD96, also known as TACTILE, is one of the members of the immunoglobulin gene superfamily and belongs to the type I transmembrane glycoprotein. It is an inhibitory immune receptor, which is mainly expressed in T cells and NK cells binds to ligands such as CD155 and CD111, and regulates cell adhesion and cytokine secretion. It plays important roles in multiple tumors, but its expression and function in glioma are unclear.
Function of Target CD96
Enhanced effect of the CD 96 / CD 155 interaction on NK cell-mediated cytotoxicity. CD96 is expressed in T cells and NK cells and is significantly upregulated upon activation. These cells play important roles in the immune system, and CD96, through its receptor-ligand interaction, can modulate the activation and function of these cells, which in turn affects the overall immune response. Because PVR is highly expressed on a variety of tumor cells, CD96 promotes NK cell recognition and killing of CD155-expressing tumor cells by binding to PVR. This suggests a potentially important role for CD96 in tumor immune surveillance and clearance. CD96 is also involved in the cell-to-cell adhesion and migration processes. By binding to ligands, CD96 may mediate cell-cell interactions and affect cell localization and migration, which has important implications in the patrolling of immune cells and the infiltration of tumor cells.
Gene Pathway of Target CD96
CD96 transduces its activation signal through the MEK-ERK pathway. CD96-mediated signaling leads to increased frequency of CD8 + T cells expressing NUR 77 and T-bet and enhanced cytotoxic effector activity, and CD96 can regulate effector T cell differentiation.
CD96 competes with TIGIT and CD96 to bind to ligands such as CD155 on the surface of tumor cells to mediate the killing function of NK cells. Although TIGIT and CD96 have other binding ligands in the tumor microenvironment, they compete for the higher binding affinity CD115 ligand and inhibit the activity of NK cells enabling tumor cells to escape killing. Low expression of CD96 elevated ERK phosphorylation in CD4 T cells and increased levels of TNF- α, IL-23, IL-17A, IL-6, and IFN- γ, indicating that CD96 is critical for AS pathogenesis and may be a potential target for the treatment of this disease.
Fig 1: CD96 Gene Pathway. (Reference source: Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of Age: CD96 Emerges as Modulator of Immune Responses. Front Immunol. 2018 May 17;9:1072.)
Alpha Lifetech Can Provide
At present, various drugs targeting CD96 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. CD96 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD96 protein products are also essential. Alpha Lifetech can provide CD96 corresponding products and help each customer's research and development. In addition, Alpha Lifetech also provides advanced expression systems and purification services to accelerate antibody research and development. Our synthesized antibody expression undergoes rigorous quality validation, including sequencing validation and functional expression analysis, to ensure high fidelity and performance. In addition, Alpha Lifetech provides customized solutions for recombinant proteins, such as codon optimization, promoter selection, and vector design, supplemented by downstream applications such as protein expression analysis to meet specific experimental needs.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64556 | 50ug,100ug,500ug | |
| ALP64512 | ALP64512-Recombinant Human CD96 Protein, Fc Tag | 50ug,100ug,500ug |
Reference
[1] Feng S, Isayev O, Werner J, Bazhin AV. CD96 as a Potential Immune Regulator in Cancers. Int J Mol Sci. 2023 Jan 9;24(2):1303.
[2] Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of Age: CD96 Emerges as Modulator of Immune Responses. Front Immunol. 2018 May 17;9:1072.
[3] Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017 Mar;276(1):112-120.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102